AbbVie (ABBV) July weekly 172.50 straddle priced into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Abbvie (ABBV) PT Raised to $210 at Truist Securities
July 25, 2024 4:12 PM EDTTruist Securities analyst Robyn Karnauskas raised the price target on Abbvie (NYSE: ABBV) to $210.00 (from $195.00) while maintaining a Buy rating.
The analyst comments "ABBV reported strong 2Q24 results with top and bottom line beats, led by Skyrizi/RInvoq. Given the share... More
Abbvie (ABBV) PT Raised to $210 at JPMorgan
July 25, 2024 3:56 PM EDTJPMorgan analyst Chris Schott raised the price target on Abbvie (NYSE: ABBV) to $210.00 (from $190.00) while maintaining a Overweight rating.
The analyst comments "Exiting 2Q results, we our updating our model and wanted to share our key changes. Overall, we are increasing our estimates to... More
